Searched for
WOCKHARDT EBITDA GROWTH
Wockhardt shares pause massive 36% rally in 5 sessions; slip 7%. What’s behind the selloff?Wockhardt shares dropped after a recent surge, as investors took profits. This followed the US FDA approval of ZAYNICH, an antibiotic for u...- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Wockhardt shares jump 9% after strong Q4 turnaround, robust FY26 growthWockhardt shares saw a significant jump on Tuesday. The pharmaceutical company reported a strong turnaround in its March quarter performanc...
- Wockhardt shares jump 17%, hit fresh 52-week highWockhardt extended its winning streak for the third straight session, drawing strong investor interest with trading volumes surging over 4....
- Wockhardt Q2 Results: Net loss narrows to Rs 16 crore, revenue rises 7%Drugmaker Wockhardt on Wednesday reported a net loss of Rs 16 crore in Q2FY25 led by improved performance across UK, India and emerging mar...
- Wockhardt Q1 Results: Net loss narrows to Rs 16 croreThe Mumbai-based drug maker reported a net loss of Rs 136 crore in Q1FY25. Revenue rose 14% year-on-year (y-o-y) to Rs.747 crore in Q1FY25 ...
- Wockhardt reports net loss of Rs 237 crore in Q4FY23Wockhardt had agreed to pay $36 million and interest over nine installments between 2022 and 2025 to the State of Texas in a drug pricing c...
- Dr Reddy’s Q2 numbers in line with estimatesDr Reddy’s has come out with a decent set of numbers on revenue, EBITDA and profitability fronts, says Nikhil Shetty.
- Brokerages raise Dr Reddy’s EPS estimate, but upside looks cappedAnalysts expect the acquisition to be funded through a bridge loan, with quick de-leveraging by FY22 through internal accruals.
- Cipla, PAG eye Wockhardt’s formulations businessWockhardt employs more than 7,000 people and has a presence in the US, Britain, Ireland, Switzerland, France, Mexico, Russia and other coun...
- Wockhardt has focused on consolidation in Q1: Habil Khorakiwala“We expect to introduce two new drugs in Indian market next year.”
- Look at Lupin, Sun Pharma or Torrent Pharma: Avinnash GorakssakarIn a chat with ET Now, Avinnash Gorakssakar, Precision Investment, says the two-wheeler market will underperform for a couple of quarters
- Brokers' Call: Wockhardt, SBI and ApolloBofA-ML is optimistic on Wockhardt's growth prospects, led by a differentiated US pipeline, as well as an improving growth trajectory in it...
- Analysts bullish on Wockhardt due to its proven growth potentialPreviously a bankruptcy case, the firm has emerged stronger and is trading at a discount to its peers.
- Macquarie maintains 'outperform' rating on WockhardtMacquarie has maintained a 'Outperform' rating on Wockhardt with an increased target price of Rs 1,575. Wockhardt expects total sales to gr...
- Wockhardt clears the debt mess, posts 95% YoY growth in Q1The company's consolidated revenues grew by 35% at Rs 1426 cr as against Rs 1053 cr last year, during the same quarter.
- Wockhardt: Will investors forgive the company?Forget its financial and legal woes, Habil Khorakiwala wants the world to notice that Wockhardt is on the road to recovery.
- Investors unwilling to forgive Wockhardt, promoter for failingsForget its financial and legal woes, Habil Khorakiwala wants the world to notice that Wockhardt is on the road to recovery.
- Wockhardt sells nutritionals biz to AbbottWockhardt has sold its nutritionals business comprising top-selling brands Farex, Protinex, Dexolac and Nusobee, and manufacturing units at...
- Wockhardt buys out Irish co for Rs 690 crMumbai-based pharmaceutical firm Wockhardt on Tuesday said the company has acquired Pinewood Laboratories, one of the largest and fastest g...
Load More
